2-Chlorophenylboronic acid | CAS:3900-89-8

We serve 2-Chlorophenylboronic acid CAS:3900-89-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Chlorophenylboronic acid

Product Name: 2-Chlorophenylboronic acid
Other Name:
2-Chlorophenylboronic acid
o-chloro-Benzeneboronic acid
Chlorobenzeneboronic acid
2-Chlorobenzeneboronic Acid
ortho-chlorophenylboronic acid
2-Chlorophenyl-dihydroxyborane
CAS No: 3900-89-8
MF: C6H6BClO2
MW: 156.37500
Density: 1.32 g/cm3
Boiling point: 306.3ºC at 760 mmHg
Melting point: 92-102 °C(lit.)
Flash point: 139ºC
Refractive index: 1.557
UN Number: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 2-Chlorophenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chlorophenyl-dihydroxyborane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ortho-chlorophenylboronic acid Use and application,2-Chlorophenylboronic acid technical grade,usp/ep/jp grade.


Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.2-Biphenylboronic acid manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.(E)-3-(4-Amino-3,5-dimethylphenyl)acrylonitrile hydrochloride supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.1,2,3-Trifluoro-4-methylbenzene vendor DPH and BPHC continue to work closely with the CDC to maintain vigilance during this virus outbreak.The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China.